Please use this identifier to cite or link to this item:
10.1186/s13053-018-0092-2
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sæther, Nikolai Havn | - |
dc.contributor.author | Skuja, Elina | - |
dc.contributor.author | Irmejs, Arvids | - |
dc.contributor.author | Maksimenko, Jelena | - |
dc.contributor.author | Miklasevics, Edvins | - |
dc.contributor.author | Purkalne, Gunta | - |
dc.contributor.author | Gardovskis, Janis | - |
dc.date.accessioned | 2021-06-22T13:05:01Z | - |
dc.date.available | 2021-06-22T13:05:01Z | - |
dc.date.issued | 2018-04-27 | - |
dc.identifier.citation | Sæther , N H , Skuja , E , Irmejs , A , Maksimenko , J , Miklasevics , E , Purkalne , G & Gardovskis , J 2018 , ' Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer : A retrospective cohort analysis and literature review ' , Hereditary cancer in clinical practice , vol. 16 , no. 1 , 9 . https://doi.org/10.1186/s13053-018-0092-2 | - |
dc.identifier.issn | 1731-2302 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/5420 | - |
dc.description | Publisher Copyright: © 2018 The Author(s). | - |
dc.description.abstract | Background: There is increasing evidence of high platinum sensitivity in BRCA-associated breast cancer. However, evidence from randomized trials is lacking. The aim of this study was to analyze the results of platinum-based chemotherapy for BRCA1-positive breast cancer in a neoadjuvant setting. Methods: A retrospective study was performed by obtaining information from patient files. The results were compared with the available data from a literature review. Results: Twelve female patients with BRCA1 gene mutations who had stage I to III breast cancers were eligible for evaluation. They received platinum-based neoadjuvant chemotherapy between 2011 and 2016. Eleven patients received a combination of cisplatin and doxorubicin, and one patient received carboplatin and docetaxel. All patients underwent mastectomy after chemotherapy. Ten patients (83%) achieved pathological complete remission (pCR). The observed pCR rate was comparable to existing results found in similar studies. Conclusion: The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role of platinum-based therapies in BRCA1-positive breast cancer. | en |
dc.format.extent | 5 | - |
dc.format.extent | 549560 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | Hereditary cancer in clinical practice | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | BRCA1 | - |
dc.subject | Breast cancer | - |
dc.subject | Cisplatin | - |
dc.subject | Neoadjuvant | - |
dc.subject | PCR | - |
dc.subject | Platinum | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | Oncology | - |
dc.subject | Genetics(clinical) | - |
dc.subject | SDG 3 - Good Health and Well-being | - |
dc.title | Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer : A retrospective cohort analysis and literature review | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.1186/s13053-018-0092-2 | - |
dc.contributor.institution | Rīga Stradiņš University | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85046120615&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Platinum_based_neoadjuvant_chemotherapy.pdf | 536.68 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.